Clinical and pharmacological group: & nbsp

Means that affect the metabolism of the prostate gland, and correctors urodynamics

Included in the formulation
  • Vitaprost®
    suppositories rect. 
    NIZHFARM, JSC     Russia
  • Prostatylene®
    suppositories rect. 
  • Prostatylene®
    lyophilizate w / m 
  • Prostatylene®
    suppositories rect. 
  • Samprost
    lyophilizate w / m 
    SAMSON-MED, LLC     Russia
  • Uroprost
    suppositories rect. 
    ALTFARM, LLC     Russia
  • Uroprost-D
    suppositories rect. 
    PATENT-FARM, CJSC     Russia
  • АТХ:

    G.04.B.X   Other drugs for the treatment of urological diseases

    Pharmacodynamics:

    Combined drug, has an organotropic effect on the prostate. Reduces the degree of edema, leukocyte infiltration of the prostate, normalizes the secretory function of epithelial cells, increases the number of lecithin grains in the secretion of the acini, stimulates the muscle tone of the bladder. Reduces thrombus formation, has antiaggregant activity, prevents the development of venous thrombosis in the prostate gland.

    Extract of the prostate improves microcirculation of blood in the wall of the bladder due to the expansion of intact vessels (the effect of vasodilation), thereby facilitating the restoration of oxygen delivery to tissues experiencing hypoxia, which stimulates physiological repair.It has an anti-inflammatory effect by improving the processes of trophic wall of the bladder and stimulation of regenerative processes. Activation of the organ blood flow improves the adaptive and contractile activity of the detrusor, increasing the capacity of the bladder.

    A decrease in the detrusor ischemia can explain the marked decrease in bladder hyperactivity, which continues after the end of the drug.

    Pharmacokinetics:No data.
    Indications:Chronic prostatitis, conditions before and after operations on the prostate gland, benign prostatic hyperplasia, prevention of exacerbations of chronic abacterial prostatitis (for tablets).

    XIV.N30-N39.N31.1   Reflex bladder, not elsewhere classified

    XIV.N30-N39.N31.2   Neurogenic weakness of the bladder, not elsewhere classified

    XIV.N40-N51.N40   Hyperplasia of the prostate

    XIV.N40-N51.N41.1   Chronic prostatitis

    XIV.N40-N51.N41.8   Other inflammatory diseases of the prostate

    XXI.Z80-Z99.Z98.8   Other specified post-surgical conditions

    XVIII.R30-R39.R39.1   Other difficulties associated with urination

    Contraindications:Hypersensitivitytion.
    Carefully:No data
    Pregnancy and lactation:The drug is not prescribed to women.
    Dosing and Administration:

    Intramuscularly, 5-10 mg, once a day, for 5-10 days. Lyophilisate before injection is dissolved in 1 ml of 0.25-0.5% solution of procaine, 0.9% NaCl solution or water for injection. If necessary, repeat the course (after 1-6 months).

    Rectal, 1 candle after a bowel movement or enema 1 time per day. After the introduction, it is desirable to stay in bed for 30-40 min. Duration of treatment - at least 10 days - with chronic prostatitis, at least 15 days - with benign prostatic hyperplasia.

    Inside 1 tab. 2 times / day. Duration of treatment with benign prostatic hyperplasia not less than 30 days; at chronic prostatitis - not less than 10 days.

    For prevention of exacerbations of chronic prostatitis apply to 1 tab. 2 times / day for at least 30 days - 1-2 times / year.

    Side effects:

    Allergic reactions: urticaria.

    In case of allergic reactions should stop treatment, prescribe antihistamines.

    Overdose:Not toxic, no overdose has been observed.
    Interaction:Compatible with antibacterialmedications used to treat prostatitis.
    Special instructions:

    Impact on the ability to drive vehicles and manage mechanisms

    Does not affect on the ability to engage in potentially hazardous activities that require special attention and quick reactions, for example, vehicle management.

    Treatment of chronic prostatitis and conditions before and after surgical interventions on the prostate gland should be comprehensive, suggesting along with the prescription of the drug tablets the use of different groups of medicines and non-pharmacological methods of treatment.

    Clinical studies aimed at assessing the effect of the drug on spermatogenesis in patients with infertility, which developed against a background of chronic prostatitis, allowed to establish a positive effect of the drug on spermatogenesis. The drug can be recommended to patients with a secretion-toxic form of infertility, developed against a background of chronic prostatitis.

    Instructions
    Up